Phase 2 study initiates to assess NA-931's safety and efficacy, alone or with Tirzepatide, for overweight/obesity

The global prevalence of obesity and overweight continues to rise, posing significant public health challenges due to associated comorbidities like type 2 diabetes, cardiovascular disease, and metabolic dysfunction-associated steatotic liver disease (MASLD). Current pharmacological treatments, such as GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists like Tirzepatide, have demonstrated substantial weight loss and metabolic improvements. However, there remains a need for novel therapeutic strategies, potentially involving combination therapies, to enhance efficacy, improve tolerability, or address non-responders. Investigating new compounds like NA-931, especially in conjunction with established highly effective agents, could unlock synergistic benefits and provide more comprehensive weight management solutions.

This Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group study is designed to assess the efficacy and safety of NA-931 as a monotherapy or in combination with Tirzepatide in adult men and women who are overweight or obese. Participants will be randomized into several arms, receiving either NA-931 alone, Tirzepatide alone, NA-931 in addition to Tirzepatide, or placebo. The primary endpoints will focus on changes in body weight and the incidence of adverse events, evaluated over a specified treatment duration. Specific doses, routes, and frequencies of administration for NA-931 and Tirzepatide will be defined by the study protocol, aiming to establish optimal therapeutic regimens and characterize the safety profile of these interventions.

This Phase 2 study is currently active but not yet recruiting, meaning no efficacy or safety results are available from the abstract. The study aims to gather data on the effects of NA-931, both as a standalone treatment and when combined with Tirzepatide, on weight reduction and overall tolerability in overweight and obese adults. The primary outcome measures will include changes in body weight from baseline and the frequency and severity of adverse events across the different treatment arms. Future results are expected to provide insights into the potential of NA-931 as a novel therapeutic agent for obesity and its synergistic effects when co-administered with a potent dual GLP-1R/GIPR agonist like Tirzepatide. Specific numerical data regarding weight loss percentages, statistical significance (p-values), or adverse event rates are not yet reported.